Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Br J Clin Pharmacol ; 69(1): 15-22, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20078608

RESUMEN

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Calcitonin gene-related peptide (CGRP) was first described as a potent vasodilator. * CGRP is also increasingly recognized as a key player in the pathophysiology of migraine, and CGRP receptor antagonists potentially offer a new approach for treating migraine. * A novel pharmacodynamic assay to measure CGRP receptor antagonist activity non-invasively in humans has been developed, which involves measuring the increase in dermal blood flow induced by topical application of capsaicin on the forearm. WHAT THIS STUDY ADDS: * This study shows that the novel oral CGRP receptor antagonist, telcagepant, inhibits the increases in dermal blood flow induced by the topical application of capsaicin on the human forearm. * This experimental medicine model may have utility to assist in dose selection for the development of CGRP receptor antagonists. AIMS: To evaluate inhibition of capsaicin-induced increase in dermal blood flow (DBF) following telcagepant (MK-0974), a potent and selective orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine. METHODS: A three-period crossover study in 12 healthy adult men. Each subject received a single oral dose of telcagepant 300 mg, telcagepant 800 mg or placebo at 0 h, followed 0.5 and 3.5 h later by two topical doses of 300 and 1000 microg capsaicin per 20 microl water-ethanol mixture. Capsaicin was applied at two sites on the volar surface of the subjects' left and right forearms. DBF was assessed by laser Doppler perfusion imaging immediately before ('baseline'), and 0.5 h after each capsaicin application at 1 and 4 h. Plasma samples to determine telcagepant concentrations were collected immediately after laser Doppler perfusion imaging. A pharmacodynamic model was developed to explore the relationship between plasma concentration and inhibition of capsaicin-induced increase in DBF. RESULTS: Geometric mean plasma concentrations after dosing with 300 mg and 800 mg telcagepant were 720 and 1146 nm, respectively, at 1 h, vs. 582 and 2548 nm, respectively, at 4 h. The pharmacodynamic model suggested that the EC(90) for telcagepant inhibition of capsaicin-induced increases in DBF was 909 nm. CONCLUSIONS: Telcagepant inhibits the increases in DBF induced by the topical application of capsaicin on the human forearm. This experimental medicine model may have utility to assist in dose selection for the development of CGRP receptor antagonists.


Asunto(s)
Azepinas/farmacología , Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina , Capsaicina/farmacología , Imidazoles/farmacología , Flujo Sanguíneo Regional/efectos de los fármacos , Piel/irrigación sanguínea , Vasodilatadores/farmacología , Administración Oral , Administración Tópica , Adolescente , Adulto , Azepinas/administración & dosificación , Azepinas/metabolismo , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Antebrazo/irrigación sanguínea , Humanos , Imidazoles/administración & dosificación , Imidazoles/metabolismo , Flujometría por Láser-Doppler , Masculino , Persona de Mediana Edad , Modelos Biológicos , Adulto Joven
2.
Cell Transplant ; 11(7): 637-52, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12518891

RESUMEN

A major limitation to the effectiveness of grafts of fetal ventral mesencephalic tissue for parkinsonism is that about 90-95% of grafted dopaminergic neurones die. In rats, many of the cells are dead within 1 day and most cell death is complete within 1 week. Our previous results suggest that a major cause of this cell death is the release of toxins from the injured CNS tissue surrounding the graft, and that many of these toxins have dissipated within 1 h of inserting the grafting cannula. In the present experiments we measured the change over time in the concentration of several potential toxins around an acutely implanted grafting cannula. We also measured the additional effect of injecting suspensions of embryonic mesencephalon, latex microspheres, or vehicle on these concentrations. Measurements of glutamate, aspartate, and dopamine by microdialysis showed elevated levels during the first 20-60 min, which then declined to baseline. In the first 20 min glutamate levels were 10.7 times, aspartate levels 5 times, and dopamine levels 24.3 times baseline. Potassium levels increased to a peak of 33 +/- 10.6 mM 4-5 min after cannula insertion, returning to baseline of <5 mM by 30 min. Injection of cell suspension, latex microspheres, or vehicle had no significant effect on these levels. We then assayed the effect of high concentrations of glutamate, aspartate, dopamine, and potassium on dopaminergic neuronal survival in E14 ventral mesencephalic cultures. In monolayer cultures only dopamine at 200 microM showed toxicity. In three-dimensional cultures only the combination of raised potassium, dopamine, glutamate, and aspartate together decreased dopaminergic neuronal survival. We conclude that toxins other than the ones measured are the main cause of dopaminergic cell death after transplantation, or the effects of the toxins measured are enhanced by anoxia and metabolic challenges affecting newly inserted grafts.


Asunto(s)
Cuerpo Estriado/cirugía , Supervivencia de Injerto/fisiología , Neuronas/metabolismo , Trastornos Parkinsonianos/terapia , Trasplante de Células Madre/métodos , Células Madre/metabolismo , Sustancia Negra/trasplante , Animales , Ácido Aspártico/metabolismo , Ácido Aspártico/toxicidad , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Cuerpo Estriado/inmunología , Cuerpo Estriado/fisiopatología , Dopamina/metabolismo , Dopamina/toxicidad , Aminoácidos Excitadores/metabolismo , Aminoácidos Excitadores/toxicidad , Espacio Extracelular/metabolismo , Femenino , Ácido Glutámico/metabolismo , Ácido Glutámico/toxicidad , Supervivencia de Injerto/efectos de los fármacos , Neuronas/efectos de los fármacos , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/fisiopatología , Potasio/metabolismo , Potasio/toxicidad , Ratas , Ratas Endogámicas , Células Madre/efectos de los fármacos , Sustancia Negra/citología , Sustancia Negra/embriología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA